Search

This month we’re wading deeper into the MedTech space with a life sciences company that’s commercializing a disruptive technology that could diagnose disease in seemingly healthy people.
It’s an exciting story of a young company that appears to be in the early innings of its growth curve, but has made it far enough with respect to technology development, customers and strategic partnerships to attract attention from larger investors.
Revenue was up 60% in 2018, and is projected to keep growing at a rapid rate. All the details are inside this month’s Issue.

With Thanksgiving and a long holiday weekend coming up, it’s a good time to do a little “self scouting.”

So far, earnings season hasn’t had that much of an impact on the overall market. I don’t think investors know quite what to make of this quarter. It’s bad. But everyone knows that going in.

While the market continues to move forward, The “Buffett Indicator,” which takes the broadest Wilshire 5000 Index and divides it by the annual U.S. GDP, is now at a record high. In doing the math, the Buffett Indicator stands at about 194%. This figure is well above the 159% seen just before the dot-com bubble.

The market is mixed so far today—as of 1145 am, the Dow is off 44 points and the Nasdaq is up 25 points, though many growth stocks are again acting well. In recent issues and updates we’ve written repeatedly about the market’s on-again, off-again, tricky and challenging environment, while at the same time seeing a lot of potential multi-month setups among growth stocks. Oftentimes, what such an environment “needs” is a shakeout on some scary headline news to clear the decks.

SPACs and growth stocks rose in tandem in 2020 and 2021. Now both are struggling in the new bear market. One has more immediate upside.

Last week was another doozy for the bulls, with the major indexes suffering a good-sized decline and many growth stocks taking it on the chin. With the major evidence still pointed down, we continue to advise holding plenty of cash and doing little on the buy side. That said, it’s also important to remain flexible, as there remains plenty of underlying potential positives, including another round of hugely pessimistic sentiment measures and a positive divergence in the broad market. As we’ve written before, if something actually goes right in the world, it’s possible the bulls could make a run at things, but we have to see it for more than a day or two to believe it. Our Market Monitor remains at a level 3.

This week’s list actually has a lot of names that look poised for intermediate-term moves … if the market can get out of its own way. Our Top Pick is an old friend in the medical device space that actually has four months of positive momentum on its chart.

Top forever stock #8 in my 10-part series on forever stocks is one some people are calling the Netflix of China. And it just came public this year.

As U.S. markets stall, European stocks are a good place to find growth right now. And these three stocks look particularly appealing.

With major equity indexes toying with all-time highs, people are feeling pretty good about the market.

I’ve written here before about why undervalued stocks are a dividend investor’s best friend. In short, yields go up when prices go down, so buying dividend-paying stocks when they’re undervalued is a good way to “lock in” higher yields for your portfolio. In today’s Dividend Edition, I have two timely ideas...